Suggested remit: To appraise the clinical and cost effectiveness of spesolimab within its marketing authorisation for treating acute generalised pustular psoriasis.
Status In progress
Technology type Medicine
Decision Selected
Process TA
ID number 3963

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
16 March 2023 We had previously said that this appraisal was expected to start in approximately early-February 2023. The company have asked NICE to delay the appraisal. The appraisal will therefore be rescheduled and an update on the revised timelines will be provided when further information is available.
26 October 2022 (10:00) Scoping workshop
07 September 2022 - 05 October 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 September 2022 In progress. Scoping commencing

For further information on our processes and methods, please see our CHTE processes and methods manual